Using advanced imaging to predict lymph node spread in high-risk prostate cancer
MC230504 Safe Omission of Pelvic Lymph Node Dissection (SOuND ) During Radical Prostatectomy: Diagnostic Accuracy of rhPSMA-7.3(18F) PET/CT, mpMRI and Patient Clinical Factors to Predict Lymph Node Metastasis
This study is testing a new imaging method to see if it can help doctors predict whether high-risk prostate cancer has spread to lymph nodes before surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 30 Years to 85 Years |
| Sex | Male |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06389786 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of 18F-rhPSMA-7.3 PET/MRI imaging in predicting lymph node metastasis in patients with localized high-risk prostate cancer prior to undergoing radical prostatectomy. The study aims to assess the diagnostic accuracy of this imaging technique, including its specificity and predictive values for lymph node positivity. Patients will receive the imaging scan and be monitored for biochemical recurrence post-surgery. The trial includes a follow-up period to track outcomes related to prostate-specific antigen levels.
Who should consider this trial
Good fit: Ideal candidates are male patients aged 30 to 85 with untreated high-risk localized prostate cancer scheduled for radical prostatectomy.
Not a fit: Patients with high-risk cancer planned for neoadjuvant therapy or those with a history of significant immunosuppressive treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate staging of prostate cancer, allowing for better treatment planning and potentially improved patient outcomes.
How similar studies have performed: Other studies utilizing PSMA PET imaging have shown promising results in improving diagnostic accuracy for prostate cancer staging.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male subjects ≥ 30 and ≤ 85 years old * Primary diagnosis of prostate cancer selected for surgical intervention (radical prostatectomy with extended lymph node dissection) * Primary diagnosis of untreated American Urological Association (AUA) guidelines high-risk localized prostate cancer, hormone-naïve prostate cancer via contrast enhanced prostate MRI + tissue sampling * Planned elective radical prostatectomy with extended pelvic lymph node dissection * Clinical oligometastatic disease with ≤ 3 nodes positive on preoperative standard of care imaging of prostate region within 6 months of surgery * Patient agrees to comply with the investigator instructions * Patient agrees to comply with the follow-up surveillance schedule * Have ability to provide full written consent Exclusion Criteria: * High-risk cancer planned for neoadjuvant therapy * Patients with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study * Patients that have had prior hormonal therapy such as Lupron or oral antiandrogens ≤ 12 weeks prior to registration * Clinical oligometastatic disease with \> 3 nodes positive preoperative standard of care imaging of prostate region * Previous history of pelvic radiation * Patients with obesity defined as body mass index (BMI) \> 40 kg/m\^2 * History of prior laparoscopic inguinal hernia repair with mesh * Scheduled at the time of screening to undergo chemotherapy, radiation, hormone therapy, or open surgery during the study period * Inability to lie still for 75 minutes during 18F-rhPSMA-7.3 PSMA PET-MRI imaging * Any neurologic disorder or psychiatric disorder that might confound postsurgical assessments * Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment * Received administration of an investigational drug within 30 days prior to study registration, and/or has planned administration of another investigational product or procedure during participation in this study
Where this trial is running
Jacksonville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Ram A. Pathak, MD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.